Today: 20 March 2026
Joby Aviation stock (JOBY) in focus after Ohio factory deal as CPI looms
11 January 2026
2 mins read

Joby Aviation stock (JOBY) in focus after Ohio factory deal as CPI looms

New York, Jan 10, 2026, 18:25 EST — The market has closed.

  • Joby shares closed Friday roughly 0.9% higher at $15.39, following a volatile trading session.
  • The air-taxi manufacturer revealed a deal to acquire a manufacturing facility in Ohio as it pushes forward with scaling up production.
  • Traders are now focused on Tuesday’s U.S. inflation figures and Joby’s upcoming earnings report as key near-term indicators.

Shares of Joby Aviation climbed roughly 0.9% Friday, closing at $15.39 on volume near 34 million. The stock fluctuated between $14.97 and $16.01 throughout the session.

This move is significant because investors have fixated on one key issue in this segment: whether electric air-taxi companies can scale production without derailing schedules or inflating costs. Joby and its rivals are still navigating certification and manufacturing hurdles, and their stock prices hinge on hitting those targets.

Joby is advancing its electric vertical takeoff and landing aircraft, or eVTOLs—planes that lift off like helicopters before switching to winged flight. This week, it announced a deal to buy a second manufacturing facility near Dayton, Ohio, covering over 700,000 square feet. The move supports a plan to boost production to four aircraft per month by 2027. CEO JoeBen Bevirt said, “This site will not only support our near-term plan to double production, it can also serve as a base for significant future growth.” SEC

A regulatory filing clarified the details. A Joby subsidiary has agreed to purchase the property for $61.5 million and will deposit $1 million in escrow. The closing depends on due diligence on the title and financing linked to the seller, the filing revealed. SEC

The sector drew notice beyond CES buzz. Archer Aviation announced Thursday it will tap Nvidia’s IGX Thor platform to build aviation AI tech, underscoring how eVTOL firms are selling investors on entire “systems” approaches, not just planes. Archer Aviation

Macro factors could still drive the next big shift. The U.S. Consumer Price Index for December 2025 hits Tuesday, Jan. 13 at 8:30 a.m. ET. This report has the potential to reshape rate forecasts and shake up appetite for high-growth stocks. Bureau of Labor Statistics

The Federal Reserve will hold its next policy meeting on Jan. 27-28, with interest rate moves taking a backseat as markets adjust post-holidays. Federal Reserve

JOBY has been bouncing around the $15 mark, with traders seeing it as a key short-term level. The $16 area is now emerging as the next obstacle if momentum picks up again.

Investors will zero in on the straightforward details: how fast Joby can convert new floor space into real production, and the impact on expenses. Any news on capital requirements, equipment schedules, or hiring—no matter how minor—could sway a stock that still hinges on “next step” developments.

The downside risk is all too familiar. Delays in certification or hiccups in scaling production due to supply-chain or cash issues could quickly undermine the 2027 output target, sending the stock lower in short order.

Joby hasn’t announced when it plans to release its next earnings, but MarketBeat projects the report will drop on Wednesday, Feb. 25, following previous patterns. Investors will focus on any updates about cash burn and expect clarity on how the Ohio expansion aligns with the production schedule. MarketBeat

Stock Market Today

  • Ocugen's Gene Therapy Pipeline Eyes Major 2026-2027 Milestones with Retinal Programs
    March 20, 2026, 9:35 AM EDT. Ocugen (OCGN) is set for a pivotal 2026-2027 with three retinal gene therapy candidates targeting retinitis pigmentosa, Stargardt disease, and geographic atrophy. The lead candidate, OCU400, has completed Phase III enrollment and aims for a rolling biologics license application by Q3 2026 and top-line data in Q1 2027. OCU400 uses a gene-agnostic modifier therapy to treat multiple mutations with one injection. Meanwhile, OCU410ST for Stargardt disease is in a Phase II/III study, with interim data expected in Q3 2026 and FDA filing planned for H1 2027. Both programs fill high unmet medical needs with no approved treatments. Regulatory applications and data readouts heavily influence OCGN's near-term stock catalysts, making timeline execution critical for investors.
Zeta Global stock ends week near a 52-week high as filings flag stake trim, planned sales
Previous Story

Zeta Global stock ends week near a 52-week high as filings flag stake trim, planned sales

Plug Power stock (PLUG) slides after TD Cowen downgrade as Walmart deal and dilution vote near
Next Story

Plug Power stock (PLUG) slides after TD Cowen downgrade as Walmart deal and dilution vote near

Go toTop